Mark Bach
Chief Tech/Sci/R&D Officer bij STRUCTURE THERAPEUTICS INC.
Vermogen: 58 415 $ op 29-02-2024
Profiel
Dr. Mark A. Bach, MD, is Senior Vice President-Clinical Development bij Ascendis Pharma A/S. Dr. Bach was voordien werkzaam als Chief Executive Officer bij Accumulus Synergy, Inc, als Head-Asia Pacific Medical Sciences bij Janssen Pharmaceuticals, Inc, als Vice President-Research & Development bij Janssen Pharmaceutical KK, en als VP-Clinical Research Operations Worldwide bij Merck & Co, Inc. Hij behaalde zijn doctoraatsdiploma aan het Carleton College, een doctoraatsdiploma aan de Universiteit van Chicago en een doctoraatsdiploma aan het Baylor College of Medicine.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
15-03-2024 | 4 320 ( 0.00% ) | 58 415 $ | 29-02-2024 |
Actieve functies van Mark Bach
Bedrijven | Functie | Begin |
---|---|---|
STRUCTURE THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01-06-2021 |
Eerdere bekende functies van Mark Bach
Bedrijven | Functie | Einde |
---|---|---|
Accumulus Synergy, Inc | Chief Executive Officer | 01-10-2020 |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | 01-08-2019 |
Janssen Pharmaceutical KK
Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Chief Tech/Sci/R&D Officer | 01-11-2012 |
MERCK & CO., INC. | Corporate Officer/Principal | 01-01-2010 |
ASCENDIS PHARMA A/S | Chief Tech/Sci/R&D Officer | - |
Opleiding van Mark Bach
Carleton College | Undergraduate Degree |
The University of Chicago | Doctorate Degree |
Baylor College of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
ASCENDIS PHARMA A/S | Health Technology |
STRUCTURE THERAPEUTICS INC. | Commercial Services |
Bedrijven in privébezit | 3 |
---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Janssen Pharmaceutical KK
Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Health Technology |
Accumulus Synergy, Inc |